pneumequine, emulsie voor injectie voor paarden
boehringer ingelheim animal health netherlands bv - geinactiveerd paarderhinopneumonitisvirus - emulsie voor injectie - equine rhinopneumonitis virus vaccine - paarden
flumequine 10% wsp, poeder voor oraal gebruik voor kalveren en kippen
kepro b.v. - flumequine - poeder voor oraal gebruik - flumequine 100 mg/g, - flumequine - kippen; runderen
flumiquil 50 % pot
ceva santé animale - flumequine 50 g - poeder voor oraal gebruik - 50 % - flumequine 500 mg/g - flumequine - pluimvee; rund; varken
flumiquil 10 % or. opl.
ceva santé animale - flumequine 100 mg/ml - drank - 10 % - flumequine 100 mg/ml - flumequine - pluimvee; rund
enterflume 50 % 500 mg/g or. opl. (pdr.)
dopharma (research) - flumequine 500 mg/g - poeder voor drank - 500 mg/g - flumequine 500 mg/g - flumequine - pluimvee; rund
enterflume varken, poeder voor gebruik in drinkwater voor varkens
dopharma research b.v. - flumequine - poeder voor gebruik in drinkwater - flumequine 500 mg/g, - flumequine - varkens
enterflume kalf, kip, poeder voor oplossing voor oraal gebruik voor kalveren en kippen
dopharma research b.v. - flumequine - poeder voor gebruik in drinkwater/melk - flumequine 500 mg/g, - flumequine - kalveren; niet eierleggende kippen
porcilis pcv m hyo
intervet international b.v. - porciene circovirus type 2 (pcv2) orf2 subunit antigeen, mycoplasma hyopneumoniae j stam geïnactiveerd - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - varkens (voor de mesterij) - voor de actieve immunisatie van varkens om viremie te verminderen, viruslading in longen en lymfoïde weefsels, virusafscheiding veroorzaakt door infectie met varkenscircovirus type 2 (pcv2) en ernst van longlaesies veroorzaakt door mycoplasma hyopneumoniae-infectie. om het verlies van de dagelijkse gewichtstoename tijdens de eindfase te verminderen in het kader van infecties met mycoplasma hyopneumoniae en / of pcv2 (zoals waargenomen in veldonderzoeken).
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - varkens - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologicals voor suidae - varkens (voor de mesterij) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.